Retrospective Analysis for Long-Term Survivors in advanced non-small cell lung cancer - Retrospective Analysis for Long-Term Survivors in advanced non-small cell lung cancer

A total of 335 patients were recruited. Twenty-eight (8.4%) patients survived more than 5 years.Sixty-five and 93 patients received gefitinib as rechallenge and beyond progressive disease (BPD), respec-tively. A statistically significant difference in OS was observed between the patients who underwentgefitinib rechallenge and those who did not rechallenge (median: 1272 days vs. 774 days; p < 0.001), aresult supported by a DTRA. Patients treated with gefitinib BPD also showed a tendency of longer survival.Conclusions: Gefitinib rechallenge and BPD played a central role in long term survival of the patients whoinitially responded to gefitinib.